IL-2 pathway

TOKYO, Japan and NEW YORK, U.S., April 20, 2026 Astellas Pharma Inc. and Pfizer Inc. have announced that the...

SAN FRANCISCO, April 20, 2026 Nektar Therapeutics has reported compelling 52-week topline results from the Phase 2b REZOLVE-AA trial,...